The Journal of Clinical Psychiatry
May 26, 2020
George I. Papakostas, Naji C. Salloum, Rebecca S. Hock et al.
107 citations
OBJECTIVE: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting intranasal therapy for depression and is currently under development for suicidality. The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). DATA SOURCES: A systematic search of PubMed/MEDLINE was conducted up to January 2019, in addition to...
Journal of Nursing Management
May 20, 2020
Sajed Faisal Ghawadra, Khatijah Lim Abdullah, W. Choo et al.
AIM To assess the effect of a 4-week Mindfulness-Based Training intervention on improving stress, anxiety, depression, and job satisfaction among ward nurses. BACKGROUND Previous literature showed that mindfulness training is useful for helping nurses cope with stress. METHOD Nurses who have mild to moderate levels of stress, anxiety, and depression identified from a teaching hospital were...
Journal of the Neurological Sciences
May 15, 2020
Molly C Kalmoe, Alvin Janski, Charles F Zorumski et al.
N-methyl-d-aspartate receptor (NMDAR) antagonists, including ketamine and nitrous oxide, are currently intensely studied as rapid-acting antidepressant agents. Interestingly, both of these compounds are also drugs of abuse. Intravenous ketamine, a dissociative anesthetic that induces complex downstream effects via NMDARs, rapidly reduces depressive and suicidal symptoms in treatment-resistant...
The Journal of Clinical Psychiatry
May 11, 2020
Dong-Jing Fu, Dawn F. Ionescu, Xiang Li et al.
367 citations
OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of...
International Journal of Africa Nursing Sciences
May 1, 2020
Zulkiflu Argungu Musa, Soh Kim Lam, Firdaus Binti Mamat @ Mukhtar et al.
Mindfulness-Based Cognitive Therapy (MBCT) was developed to prevent relapse in people with depressive disorders, and it help individuals better understand and manage their thoughts and emotions in order to achieve relief from feelings. Objective: The objective of this paper is to review and evaluate the effectiveness of MBCT on the management of depression. Method: To find appropriate studies,...
Prescriber
May 1, 2020
Steve Chaplin
1 citation
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.
Human Brain Mapping
May 1, 2020
Joana R Loureiro, Amber M Leaver, Megha M Vasavada et al.
65 citations
Electroconvulsive therapy (ECT) and ketamine treatment both induce rapidly acting antidepressant effects in patients with major depressive disorder unresponsive to standard treatments, yet their specific impact on emotion processing is unknown. Here, we examined the neural underpinnings of emotion processing within and across patients (N = 44) receiving either ECT (N = 17, mean age: 36.8, 11.0...
Medical Science Monitor
April 27, 2020
Jie Wang, Yajun Wang, Xudong Xu et al.
80 citations
Background This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression. Material/Methods This randomized, double-blind, controlled study included 417 cervical carcinoma patients who received laparoscopic modified radical hysterectomy from April 2015 to July 2018 and who also had mild/moderate...
Journal of Clinical Psychopharmacology
April 25, 2020
Marlene P. Freeman, Rebecca S. Hock, George I. Papakostas et al.
45 citations
PURPOSE/BACKGROUND: Major depressive disorder (MDD) and obesity commonly co-occur. We sought to assess the impact of body mass index (BMI) on the acute antidepressant effects of ketamine in patients with treatment-resistant depression. METHODS/PROCEDURES: Post hoc analyses were conducted from a multisite, randomized, double-blind, placebo-controlled trial designed to assess the rapid-onset...
The Journal of Clinical Psychiatry
April 20, 2020
Ewa Wajs, Leah Aluisio, Richard Holder et al.
288 citations
OBJECTIVE: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). METHODS: This phase 3, open-label, multicenter, long-term (up to 1 year) study was conducted between October 2015 and October 2017. Patients (≥ 18 years) with TRD (DSM-5 diagnosis of major depressive disorder and nonresponse...
Pharmacological Reports
April 16, 2020
J. Kryst, Paweł Kawalec, Alicja Mikrut Mitoraj et al.
157 citations
Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains. Electronic databases (Medline via PubMed, Embase, Cochrane Library, Trip...
PLoS One
April 3, 2020
Ahmed M Alzahrani, Ahmed Hakami, Ahmad Alhadi et al.
There is a growing body of research that shows a significant association between mindfulness and mental health. However, studies on Saudi populations are still in their infancy. Mindfulness is a personal tendency to focus on the present time in a non-judgmental manner, including the interior and exterior experience of feelings and events. The first aim of this study is to examine the...
Journal of Mental Health
April 2020
Jessica M. Brooks, Veronica Muller, Jennifer Sánchez et al.
Background: Depressive symptoms complicate pain management for people with FM, with adverse consequences such as a greater need for pain medications and limited pain coping strategies. Determining risks and protective factors associated with depressive symptoms in persons with FM could inform the development and implementation of mental health interventions.Aims: To formulate and test a...
Psychological Reports
April 1, 2020
Chieko Fujisaki
AEON-HO (Altering emotional organization-holistic operation) contains methods of Naikan therapy and mindfulness. Naikan and mindfulness are originally from Buddhism tradition, and they have a high affinity. AEON-HO was conceptualized to improve attachment issues and the growth of self-actualization, because Naikan and mindfulness are known to be effective for attachment issues but partially if...
CNS Spectrums
April 1, 2020
Leslie Citrome, Allitia DiBernardo, Jaskaran Singh
Abstract: Background: Targeting of glutamate receptors is a novel approach for the treatment of major depressive disorder (MDD). This study aimed to review the usefulness for esketamine nasal spray for the management of treatment-resistant depression (TRD) using the tools of evidence-based medicine: number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed...
Cell
April 1, 2020
David Nutt, David Erritzøe, Robin Carhart-Harris
330 citations
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and...
Frontiers in Psychiatry
March 31, 2020
Kristin Heuschkel, Kim P. C. Kuypers
82 citations
Depression is a major public health problem that affects approximately 4.4% of the global population. Since conventional pharmacotherapies and psychotherapies are only partially effective, as demonstrated by the number of patients failing to achieve remission, alternative treatments are needed. Mindfulness meditation (MM) and psilocybin represent two promising novel treatments that might even...
Psychiatry Research
March 6, 2020
Jianjing Zhang, H. Tian, Jie Li et al.
13 citations
New methods for using ketamine in patients with propofol-electroconvulsive therapy-resistant depression (ECT-RD) are needed in the clinic. This study aimed to investigate the therapeutic efficacy of ketamine plus ECT in ECT-RD patients, along with the treatment-induced brain alterations. A total of 28 ECT-RD patients were intravenously injected with ketamine six times and treated with...
ACS Chemical Neuroscience
March 5, 2020
Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer et al.
211 citations
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of...
Sleep Health
March 4, 2020
David A Kalmbach, Thomas Roth, P. Cheng et al.
BACKGROUND Insomnia and depression are highly prevalent perinatal complications. Ruminating on stress is etiologically implicated in both disorders, and ruminating while trying to fall asleep has been linked to insomnia and depression during pregnancy. Incompatible with rumination is everyday mindfulness, i.e., living with intentional and nonjudgmental awareness of internal and external...